9^th World Drug Delivery Summit

Biography

Biography: Xing-Jie Liang

Abstract

Chemotherapeutics are still the primary options applicable to cancer treatments, however, the chemo-resistance developed by tumor limits their further clinical application. One way to solve this obstacle is to improve the bioavailability of anti-cancer drugs mostly with poor intracellular accumulation. Various Nanoparticle-based delivery systems (NDS) such as dendrimer, vesicles, liposomes, micelles and inorganic materials are fabricated to greatly enhance their stability and blood circulation period. Meanwhile, these NDS are also widely employed in cancer therapy owing to their improved pharmacokinetics and pharmacodynamics arising from the enhanced permeation and retention (EPR). Because traditional DDSs are poor to enter the cells and release drugs up to effective therapeutic dosage, NDS such as Nanomicelle with small size, high drug loading, controlled and sustained drug release and their potential to overcome drug resistance, a shell/core nanostructure self-assembled by amphiphilic macromolecules, constitutes a promising nanocarrier for efficient chemotherapeutics. Drug-encapsulated nanomicelles were also developed under clinical evaluation. NDS has emerged as an effective strategy for pharmaceutical formulation to deliver payloads into the targeted regions and gained particular attention in biomedical field.